ARTICLE | Company News
Karo Bio, Novalon deal
April 3, 2000 7:00 AM UTC
Karo, which is developing nuclear receptor-targeted therapeutics using structure-based drug design, will acquire Novalon in a stock transaction. Novalon is developing BioKeys, small proteins that bind...